Iterum Therapeutics plc
Datakwaliteit: 83%
ITRM
Nasdaq
Manufacturing
Chemicals
€ 0,03
▲
€ 0,03
(—)
Marktkapitalisatie: 1,60 M
Prijs
€ 0,03
Marktkapitalisatie
1,60 M
Dagbereik
€ 0,03 — € 0,05
52-Weeksbereik
€ 0,01 — € 1,42
Volume
49.297.937
Openen € 0,04
50D / 200D Gem.
€ 0,21
85,44% below
50D / 200D Gem.
€ 0,52
94,20% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -19,53 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-59,78%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio2,13
Interest Coverage-4,12
Waardering
PE (TTM)
-0,06
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,1 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -26,96 M |
| ROE | N/A | ROA | -81,06% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -19,53 M |
| ROIC | -59,78% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,13 |
| Interest Coverage | -4,12 | Asset Turnover | N/A |
| Working Capital | 7,30 M | Tangible Book Value | -26,09 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,06 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1221,46% | ||
| Market Cap | 1,60 M | Enterprise Value | 10,64 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,72 | Revenue / Share | N/A |
| FCF / Share | -0,37 | OCF / Share | -0,37 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 72,43% |
| SBC-Adj. FCF | -19,77 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 0,0 | 0,0 |
| Net Income | -24,77 M | -38,37 M | -44,43 M | -91,56 M | -52,01 M |
| EPS (Diluted) | -1,26 | -2,96 | -3,63 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -18,70 M | -47,47 M | -30,38 M | -24,54 M | -32,13 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 10,46 M | 39,99 M | 17,62 M | 10,71 M | 21,07 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 3,31 M | — | — | — | — |
| Income Tax | 240.000,0 | 613.000,0 | 301.000,0 | 705.000,0 | 743.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 44,60 M | 26,26 M | 66,83 M | 91,51 M | 32,79 M |
| Total Liabilities | 48,68 M | 32,66 M | 38,83 M | 41,28 M | 83,35 M |
| Shareholders' Equity | -4,08 M | -6,40 M | 28,00 M | 50,23 M | -50,56 M |
| Total Debt | 31,22 M | 11,22 M | 12,71 M | 6,93 M | 22,46 M |
| Cash & Equivalents | 24,13 M | 6,07 M | 21,09 M | 27,45 M | 14,51 M |
| Current Assets | 24,79 M | 25,60 M | 62,44 M | 83,27 M | 21,47 M |
| Current Liabilities | 17,61 M | 13,52 M | 9,06 M | 12,94 M | 41,70 M |
{"event":"ticker_viewed","properties":{"ticker":"ITRM","listing_kind":"stock","pathname":"/stocks/itrm","exchange":"Nasdaq","country":"US"}}